| 1. |
- Dian, E., et al.
(författare)
-
Preparation for activation measurements of concrete and PE-B4C-concrete to be applied for shielding at the European Spallation Source
- 2018
-
Ingår i: 22nd Meeting of the International Collaboration on Advanced Neutron Sources (ICANS XXII). - : Institute of Physics Publishing (IOPP).
-
Konferensbidrag (refereegranskat)abstract
- To improve the effect of the concrete below 10 MeV where iron has resonances in the cross section, a new concrete have been developed. The PE-B4C-concrete utilizes hydrogen containing PE to thermalize the neutron and boron for in situ absorption. It is of utmost importance that the activation of the shielding material itself is well-understood, since it is planned to be used at the ESS. The first steps in this direction are shown the present study, in which concrete as well as reference aluminium samples are subject to XRF measurements to precisely determine the element content. This is compared to data sheets from the vender, and simulations are carried out to predict the sample activity. The samples are planned for insertion into the the Budapest Research Reactor, followed be activity and spectral measurements.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Egyud, Matthew, et al.
(författare)
-
Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer.
- 2019
-
Ingår i: Head & neck. - : Wiley. - 1097-0347 .- 1043-3074. ; 41:5, s. 1351-1358
-
Tidskriftsartikel (refereegranskat)abstract
- Recommendations for perioperative therapy in head and neck cancer are not explicit and recurrence occurs frequently. Circulating tumor DNA is an emerging cancer biomarker, but has not been extensively explored for detection of recurrence in head and neck cancer.Patients diagnosed with head and neck squamous cell carcinoma were recruited into the study protocol. Tumors were sequenced to identify patient-specific mutations. Mutations were then identified in plasma circulating tumor DNA from pre-treatment blood samples and longitudinally during standard follow-up. Circulating tumor DNA status during follow-up was correlated to disease recurrence.Samples were taken from eight patients. Tumor mutations were verified in seven patients. Baseline circulating tumor DNA was positive in six patients. Recurrence occurred in four patients, two of whom had detectable circulating tumor DNA prior to recurrence.Circulating tumor DNA is a potential tool for disease and recurrence monitoring following curative therapy in head and neck cancer, allowing for better prognostication, and/or modification of treatment strategies.
|
|
| 5. |
- He, H. J., et al.
(författare)
-
Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements
- 2019
-
Ingår i: Journal of Molecular Diagnostics. - : Elsevier BV. - 1525-1578. ; 21:4, s. 658-676
-
Tidskriftsartikel (refereegranskat)abstract
- We conducted a multilaboratory assessment to determine the suitability of a new commercially available reference material with 40 cancer variants in a background of wild-type DNA at four different variant allele frequencies (VAFs): 2%, 0.50%, 0.125%, and 0%. The variants include single nucleotides, insertions, deletions, and two structural variations selected for their clinical importance and to challenge the performance of next-generation sequencing (NGS) methods. Fragmented DNA was formulated to simulate the size distribution of circulating wild-type and tumor DNA in a synthetic plasma matrix. DNA was extracted from these samples and characterized with different methods and multiple laboratories. The various extraction methods had differences in yield, perhaps because of differences in chemistry. Digital PCR assays were used to measure VAFs to compare results from different NGS methods. Comparable VAFs were observed across the different NGS methods. This multilaboratory assessment demonstrates that the new reference material is an appropriate tool to determine the analytical parameters of different measurement methods and to ensure their quality assurance.
|
|
| 6. |
|
|
